Kirschner
This article was originally published in The Gray Sheet
Executive Summary
Rejects Maxxim Medical's most recent offer to acquire the orthopedic device company. Maxxim had offered to pay $11.50 in cash for each of Kirschner's outstanding shares, less any break-up fee resulting from terminating its merger agreement with Biomet. On July 25, Sugar Land, Texas-based Maxxim had offered to pay either $11.50 in cash or an equivalent value in common stock, at Maxxim's discretion, for each Kirschner share, but committed itself on July 28 to payment in cash. Maxxim had hoped to lure the Timonium, Maryland-based firm away from the definitive agreement it signed with Biomet, under which each Kirschner common share will be exchanged for either $10.75 in cash or an equivalent value in Biomet common stock ("The Gray Sheet" July 25, In Brief). Kirschner notes that Biomet has made a $2 mil. earnest money deposit, "refundable under certain conditions," and that Kirschner must pay $1 mil. if it terminates the transaction under certain circumstances
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.